Alvotech Reports Record-Breaking First Half of 2025 Amid Strong Biosimilar Sales

Future Directions for Ustekinumab Biosimilars in Crohn Disease

May 3rd 2025

By Deana Ferreri, PhD

The Top 5 Biosimilar Articles for the Week of April 28

May 2nd 2025

By Cameron Santoro

Here are the top 5 biosimilar articles for the week of April 28, 2025.

Samsung Bioepis Report Signals Turning Point for US Biosimilars

May 1st 2025

By Skylar Jeremias

A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.

Biosimilars Policy Roundup: April 2025

April 30th 2025

By Skylar Jeremias

Between congressional hearings and executive orders, experts had plenty to draw on when dissecting the barriers to biosimilar access at Festival of Biologics USA to close out April 2025.

Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships

April 29th 2025

By Skylar Jeremias

Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.

FDA's Expanded Access: From Laetrile to Right to Try, Ethical Debates Over Early Drug Access

April 28th 2025

By Cameron Santoro

Christopher T. Robertson, JD, PhD, reviewed the history and ethical landscape of providing access to drugs before FDA approval, highlighting the crucial role of clinical trials and ethical safeguards at the 2025 Festival of Biologics USA.

Clinical Evidence Shows No Safety Gaps Between Biosimilar, Reference Adalimumab

April 26th 2025

By Deana Ferreri, PhD

A plain language summary for patients explains there were no differences in safety outcomes between adalimumab-adbm and the originator in a pooled analysis of the VOLTAIRE clinical trials.

The Top 5 Biosimilar Articles for the Week of April 21

April 25th 2025

By Skylar Jeremias

Here are the top 5 biosimilar articles for the week of April 21, 2025.

Addressing Patent Abuse, Reimbursement Models Key to Sustainable Biosimilar Market

April 25th 2025

By Cameron Santoro

Sonia T. Oskouei, PharmD, emphasized strategies to streamline regulations and evolve to overcome barriers and expand the availability of cost-effective biosimilar treatments across more therapeutic areas.

Unlocking Biosimilar Potential in Specialty Pharmacies With Legislative Support, Formulary Changes

April 24th 2025

By Cameron Santoro

Sophia Humphreys, PharmD, MHA, BCBBS, emphasized that legislative support and formulary changes are crucial for overcoming unique challenges in specialty pharmacies and driving the growth of biosimilar adoption, which has significant cost saving potential in the next decade.